Matilde Y. Follo - Concepedia

Author

Matilde Y. Follo

Also Known As

Follo, Matilde Y., M Y Follo, M. Follo, M.Y. Follo, Matilde Follo, Matilde Y Follo, Matilde Y. Follo, Matilde Yung Follo, Yung Follo, Matilde

136

Publications

4.2K

Citations

H-Index

Concepts

All Affiliations

University of Bologna Memorial Sloan Kettering Cancer Center East Carolina University University of Oxford Istituti di Ricovero e Cura a Carattere Scientifico

About

Matilde Y. Follo is an author at University of Bologna specializing in medicine, cell biology, and hematology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	18	2K
2	Health Sciences	4	4	693
3	Engineering	1	1	38
4	Natural Sciences	1	1	56
5	Public Health	1	1	746

Matilde Y. Follo

Publications

2.6K

Citations

H-Index

Page 1

	Year	Citations
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes Elsa Bernard, Heinz Tuechler, Peter L. Greenberg, NEJM Evidence Mixed-phenotype Acute LeukemiaPrognosisGenetic EpidemiologyDiagnosisPathology	2022	746
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes Elsa Bernard, Yasuhito Nannya, Robert P. Hasserjian, Nature Medicine Hematological MalignancyChromatinGenome StabilityMedicineMixed-phenotype Acute Leukemia	2020	606
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS Matilde Y. Follo, Carlo Finelli, Sara Mongiorgi, Proceedings of the National Academy of Sciences Hematological MalignancyMixed-phenotype Acute LeukemiaAcute Myeloid LeukemiaMds PatientsPharmacology	2009	119
Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients Maria Nyåkern, Pier Luigi Tazzari, Carlo Finelli, Leukemia Hematological MalignancyBone Marrow FailureAkt Kinase PhosphorylationMalignant Blood DisorderImmunology	2005	101
The Akt/Mammalian Target of Rapamycin Signal Transduction Pathway Is Activated in High-Risk Myelodysplastic Syndromes and Influences Cell Survival and Proliferation Matilde Y. Follo, Sara Mongiorgi, Costanza Bosi, Cancer Research	2007	90
Prospective Phase II Study on 5-Days Azacitidine for Treatment of Symptomatic and/or Erythropoietin Unresponsive Patients with Low/INT-1–Risk Myelodysplastic Syndromes Carla Filì, Michele Malagola, Matilde Y. Follo, Clinical Cancer Research	2013	68
Phosphoinositide-Phospholipase C β1 Mono-Allelic Deletion Is Associated With Myelodysplastic Syndromes Evolution Into Acute Myeloid Leukemia Matilde Y. Follo, Carlo Finelli, Cristina Clissa, Journal of Clinical Oncology	2008	61
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy Yao‐Chung Liu, Junsu Kwon, Emiliano Fabiani, New England Journal of Medicine	2022	61
Inositide-Dependent Phospholipase C Signaling Mimics Insulin in Skeletal Muscle Differentiation by Affecting Specific Regions of the Cyclin D3 Promoter Irene Faenza, Giulia Ramazzotti, Alberto Bavelloni, Endocrinology Muscle FunctionReporter GeneCyclin D3 PromoterCellular PhysiologyInsulin Signaling	2006	56
Molecular taxonomy of myelodysplastic syndromes and its clinical implications Elsa Bernard, Robert P. Hasserjian, Peter L. Greenberg, Blood	2024	52

Page 1